InnoUp Farma
Innoup Farma is a Spanish clinical-stage company specializing in nanotechnology innovations, focused on developing oral drug delivery solutions. They have developed a Nanoparticle Platform protected by international patents, aimed at improving drug bioavailability and creating vaccines and immunotherapeutic products. Their mission is to improve people's lives through research and development of innovative nanomedicine-based drugs, guided by values of passion, excellence, responsibility, and transparency.
Industries
Nr. of Employees
small (1-50)
Products
Oral paclitaxel nanoparticle formulation (clinical-stage)
Nanoparticle-encapsulated paclitaxel formulation designed to increase oral bioavailability and reduce systemic toxicity compared with intravenous reference treatments; advanced to Phase I clinical trial authorization.
Oral peanut-allergen nanoparticle immunotherapy (clinical-stage)
Nanoparticle formulation encapsulating peanut allergen intended to act as an oral immunotherapy / vaccine to treat peanut allergy; progressed to Phase I clinical study development and authorised clinical research in collaboration with clinical centres.
Oral nanoparticle vaccine candidate with inactivated virus (preclinical)
Nanoparticle-encapsulated inactivated virus formulation under preclinical development to evaluate immunogenicity for oral vaccine applications.
Oral paclitaxel nanoparticle formulation (clinical-stage)
Nanoparticle-encapsulated paclitaxel formulation designed to increase oral bioavailability and reduce systemic toxicity compared with intravenous reference treatments; advanced to Phase I clinical trial authorization.
Oral peanut-allergen nanoparticle immunotherapy (clinical-stage)
Nanoparticle formulation encapsulating peanut allergen intended to act as an oral immunotherapy / vaccine to treat peanut allergy; progressed to Phase I clinical study development and authorised clinical research in collaboration with clinical centres.
Oral nanoparticle vaccine candidate with inactivated virus (preclinical)
Nanoparticle-encapsulated inactivated virus formulation under preclinical development to evaluate immunogenicity for oral vaccine applications.
Services
Collaborative development and licensing of nanoparticle delivery platform
Partnership-based collaboration and potential licensing of a nanoparticle encapsulation platform for oral and mucosal delivery of drugs and antigens.
Clinical trial sponsorship and coordination (early-phase)
Sponsorship and coordination of Phase I clinical trials for oral nanoparticle therapeutics in collaboration with clinical sites and hospital partners.
Collaborative development and licensing of nanoparticle delivery platform
Partnership-based collaboration and potential licensing of a nanoparticle encapsulation platform for oral and mucosal delivery of drugs and antigens.
Clinical trial sponsorship and coordination (early-phase)
Sponsorship and coordination of Phase I clinical trials for oral nanoparticle therapeutics in collaboration with clinical sites and hospital partners.
Expertise Areas
- Nanoparticle-based drug delivery
- Oral drug formulation and bioavailability enhancement
- Mucosal vaccine and immunotherapy development
- Preclinical study design and execution (animal models)
Key Technologies
- Nanoparticle encapsulation
- Bioadhesive nanoparticle formulations
- Controlled-release oral formulations
- Mucosal delivery platforms (oral, intranasal, pulmonary)